Removal of Remdesivir’s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19
Minh Lê, Quentin Le Hingrat, Pierre Jaquet, Paul-Henri Wicky, Vincent Bunel, Laurent Massias, Benoît Visseaux, Jonathan Messika, Diane Descamps, Hervé Mal, Jean‐François Timsit, Gilles Peytavin
Abstract
Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir's metabolite (GS-441524) and sulfobutylether β-cyclodextrin sodium (SEBCD). Additional studies may prove informative, particularly in the evaluations of therapeutic options for coronavirus disease 2019 (COVID-19).